Table 44SGA vs. SGA - leaving the study early due to AEs (Relapse prevention)

Outcome or SubgroupkTotal NStatistical MethodEffect [95% CI]
9.1 Leaving the study early due to adverse events2465RR (M-H, Fixed, 95% CI)0.96 [0.55, 1.67]
 9.1.1 Olanzapine vs risperidone1339RR (M-H, Fixed, 95% CI)0.97 [0.51, 1.84]
 9.1.2 Olanzapine vs ziprasidone1126RR (M-H, Fixed, 95% CI)0.93 [0.30, 2.89]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.